BioCentury
ARTICLE | Product Development

Flagship’s Senda builds on Kintai’s microbe-mimicking pipeline with plant and bacteria-based delivery modalities

Emerging Company Profile: Combining four companies, Flagship builds a platform around human cells' interactions with other species

October 29, 2020 12:45 AM UTC

Flagship’s latest portfolio company mash-up brings together technologies that take advantage of microbial and plant biology to treat human disease.

Senda Biosciences rolls together four companies founded by Flagship Pioneering with $88 million of investment between them. ...